NCT00889408View on ClinicalTrials.gov

DT2219ARL for Relapsed or Refractory CD19 (+), CD 22 (+) B-Lineage Leukemia Or Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

December 2, 2013

Primary Completion Date

July 21, 2014

Study Completion Date

July 21, 2014

Conditions
LeukemiaLymphoma
Interventions
BIOLOGICAL

DT2219ARL

anti-CD19/CD22 bispecific ligand-directed toxin DT2219ARL

Trial Locations (3)

55455

Masonic Cancer Center at University of Minnesota, Minneapolis

76508

Scott and White Cancer Institute, Temple

77030-4009

M. D. Anderson Cancer Center at University of Texas, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Masonic Cancer Center, University of Minnesota

OTHER

NCT00889408 - DT2219ARL for Relapsed or Refractory CD19 (+), CD 22 (+) B-Lineage Leukemia Or Lymphoma | Biotech Hunter | Biotech Hunter